The Eversense ® CGM app has been updated globally to integrate seamlessly with Apple Health TM, according to Ascensia Diabetes Care, a global diabetes care company, manufacturer of the CONTOUR ® Blood Glucose Monitoring (BGM) system portfolio, and distributor of the Eversense ® Continuous Glucose Monitoring (CGM) system.

This implies that users of Eversense CGM Systems who have diabetes can now view their glucose data in the widely used Apple Health app in addition to other health information on the iPhone.

The Eversense E3, developed by Senseonics Holdings, Inc. (NYSE American: SENS), is the only CGM on the market with a sensor with a lifespan of up to 6 months. It is extraordinarily accurate and entirely implantable. The device transmits data to the Eversense CGM app, which allows diabetes patients to see, analyse, and share glucose data with ease while receiving notifications of changes and trends. With this upgrade, diabetic patients can now select to examine their data in Apple Health, where they can also view health data gathered by their iPhone through various apps and wearables, wherever Eversense is available.

Elaine Anderson, head of the Eversense CGM Business Unit at Ascensia Diabetes Care, said, “We are thrilled to connect the Eversense CGM System with Apple Health TM, offering our end users more option about how they see and use data to monitor their diabetes.” “This upgrade gives diabetes patients access to glucose data together with other crucial data, allowing them to get a more complete picture of their health and well-being in addition to the advantages of the Eversense CGM app. We are eager to further integrate Eversense into the linked healthcare ecosystem since it is crucial that medical equipment and digital solutions are compatible in a world that is becoming more and more digital.

Source: Prnewswire